IMVT Stock: Price, Earnings History and SEC Filings
Immunovant, Inc. (IMVT) last traded at $29.17, down 1.59% on the latest session and down 13.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.75 against an analyst estimate of $-0.66, a miss of 13.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
IMVT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.75 | $-0.66 | -13.64% |
| Mar 2026 | May 20, 2026 | $-0.73 | $-0.60 | -21.67% |
| Dec 2025 | Feb 6, 2026 | $-0.61 | $-0.72 | +15.28% |
| Sep 2025 | Nov 10, 2025 | $-0.73 | $-0.72 | -1.39% |
IMVT beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How IMVT reacts to earnings
Across its last 8 earnings releases, IMVT moved 9.2% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | +1.17% |
| 2026-05-20 | Before open | +35.26% |
| 2026-02-06 | Before open | +12.43% |
| 2025-11-10 | Before open | +0.09% |
| 2025-08-11 | Before open | -4.53% |
| 2025-05-29 | Before open | +5.60% |
| 2025-02-06 | Before open | -9.55% |
| 2024-11-07 | Before open | -4.74% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
IMVT financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2026 | – | -$506M | -$407M | – | $-2.77 |
| 2025 | – | -$414M | -$377M | – | $-2.73 |
| 2024 | – | -$259M | -$215M | – | $-1.88 |
| 2023 | – | -$211M | -$188M | – | $-1.71 |
| 2022 | – | -$157M | -$106M | – | $-1.43 |
| 2021 | – | -$107M | -$84M | – | $-1.22 |
| 2020 | – | -$66M | -$53M | – | – |
| 2019 | – | -$29M | -$29M | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for IMVT
- 8-K · Sep 3, 2026Shareholder vote
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Jul 22, 2026
- 10-K · May 20, 2026
- 8-K · May 20, 2026Results of operations, Financial statements and exhibits
- 10-Q · Feb 6, 2026
- 8-K · Feb 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Dec 12, 2025Other events, Financial statements and exhibits
- 424B5 · Dec 12, 2025
Insider filing activity
IMVT insiders filed 9 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
IMVT news
- Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026Oct 21, 2026 · finance.yahoo.com
- Immunovant (IMVT) Stock Looks Stretched On Book Value AloneOct 20, 2026 · finance.yahoo.com
- Immunovant: Batoclimab 2.0 Bull Case Flawed By Mixed Data, Competitive ThreatsOct 20, 2026 · seekingalpha.com
About Immunovant, Inc.
Immunovant, Inc. (IMVT) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in March.